Binimetinib
CAS 606143-52-6 5 FDA-DMF suppliersSmall Molecule
Overview
Binimetinib is a small molecule inhibitor of MEK1 and MEK2, proteins that play a key role in the mitogen-activated protein kinase (MAPK) signaling pathway involved in cell proliferation. It is used in the treatment of certain types of melanoma in combination with other therapies.
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Binimetinib expires 17 Oct 2033 and exclusivity 10 Oct 2026. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyMelanoma
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.